Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

omnivision ag - polymyxini b sulfas, neomycinum - collirio - polymyxini b sulfas 1.5 mg, neomycinum 3.5 mg ut neomycini sulfas, acidum boricum 16 mg, borax 2.7 mg, hypromellosum, benzalkonii chloridum 0.1 mg, aqua purificata, ad solutionem pro 1 ml. - le infezioni agli occhi - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

interdelta s.a. - polymyxini b sulfas, neomycini sulfas, dexamethasoni-21 (3-sulfobenzoas) natricus - gocce per le orecchie - polymyxini b sulfas 10000 u. i., neomycini sulfas 10 mg, dexamethasoni-21 (3-sulfobenzoas) natricus 1 mg, macrogolum 400, conserv.: thiomersalum, excipiens ad una soluzione per 1 ml. - otite - sintetica umana

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - dexamethasonum, neomycinum, polymyxini b sulfas - collirio - dexamethasonum 1 mg, neomycinum 3.5 mg ut neomycini sulfas 4.6 mg, polymyxini b sulfas 6000 u.i., natrii chloridum, polysorbatum 20, acidum hydrochloridum aut natrii hydroxidum, hypromellosum, aqua purificata, benzalkonii chloridum 40 µg, ad suspensionem pro 1 ml. - infetti infiammazione agli occhi - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

zambon svizzera sa - neomycinum, polymyxini b sulfas, fludrocortisoni acetas, lidocaini hydrochloridum monohydricum - gocce otologiche - neomycinum 7.5 mg ut neomycini sulfas, polymyxini b sulfas 10000 u.i., fludrocortisoni acetas 1 mg, lidocaini hydrochloridum monohydricum 40 mg, propylenglycolum 458.6 mg, glycerolum, acidum hydrochloridum ad ph, benzalkonii chloridum 0.1 mg, aqua purificata q.s. ad solutionem pro 1 ml corresp. 42 gutta. - otite - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - dexamethasonum, neomycinum, polymyxini b sulfas - il collirio - dexamethasonum 1 mg, neomycinum 3.5 mg ut neomycini sulfas 4.6 mg, polymyxini b sulfas 6000 u.i., adeps lanae 30 mg, propylis parahydroxybenzoas 0.1 mg, e 218 0.5 mg, vaselinum album ad unguentum pro 1 g. - infetti infiammazione agli occhi - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - toxoidum diphtheriae, toxoidum tetani, toxoidum pertosse, haemagglutininum filamentosum (b. pertussis, pertactinum (b. pertussis, il virus della poliomielite di tipo 1 inactivatus (stamm mahoney), virus e poliomielite di tipo 2 inactivatus (stamm mef-1), un virus e la poliomielite di tipo 3 inactivatus (stamm saukett), polysaccharida haemophili influenzae di tipo b 20752 conjugata con toxoido tetani - pulver und suspension zur herstellung einer injektionssuspension - i) dtpa-ipv: toxoidum diphtheriae min. 30 u.i., toxoidum tetani min. 40 u.i., toxoidum pertussis 25 µg, haemagglutininum filamentosum (b. pertussis) 25 µg, pertactinum (b. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (stamm mahoney) 40 u., virus poliomyelitis typus 2 inactivatus (stamm mef-1) 8 u., virus poliomyelitis typus 3 inactivatus (stamm saukett) 32 u., aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum corresp. natrium 1.8 mg, medium 199, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini b sulfas, polysorbatum 80, formaldehydum. ii) hib: polysaccharida haemophili influenzae typus b 20752 conjugata cum toxoido tetani 10 µg, lactosum, pro praeparatione. i) et ii) corresp. dtpa-ipv + hib: toxoidum diphtheriae min. 30 u.i., toxoidum tetani min. 40 u.i., toxoidum pertussis 25 µg, haemagglutininum filamentosum (b. pertussis) 25 µg, pertactinum (b. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (stamm mahoney) 40 u., virus poliomyelitis typus 2 inactivatus (stamm mef-1) 8 u., virus poliomyelitis typus 3 inactivatus (stamm saukett) 32 u., polysaccharida haemophili influenzae typus b 20752 conjugata cum toxoido tetani 10 µg, aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum corresp. natrium 1.8 mg, medium 199, lactosum, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini b sulfas, polysorbatum 80, formaldehydum. - aktive immunisierung gegen diphtherie, tetanus, pertussis, poliomyelitis und haemophilus influenzae typ b, ab dem vollendeten 2. lebensmonat, auffrischimpfung (4. dosis), ab dem vollendeten 12. lebensmonat - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - toxoidum diphtheriae, toxoidum tetani, toxoidum pertussis, haemagglutininum filamentosum (b. pertussis), pertactinum (b. pertussis), virus poliomyelitis typus 1 inactivatus (stamm mahoney), virus poliomyelitis typus 2 inactivatus (stamm mef-1), virus poliomyelitis typus 3 inactivatus (stamm saukett), hepatitidis b viri antigenum adnr, polysaccharida haemophili influenzae typus b 20752 conjugata cum toxoido tetani - pulver und suspension zur herstellung einer injektionssuspension - i) dtpa-hepb-ipv: toxoidum diphtheriae min. 30 u.i., toxoidum tetani min. 40 u.i., toxoidum pertussis 25 µg, haemagglutininum filamentosum (b. pertussis) 25 µg, pertactinum (b. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (stamm mahoney) 40 u.i., virus poliomyelitis typus 2 inactivatus (stamm mef-1) 8 u.i., virus poliomyelitis typus 3 inactivatus (stamm saukett) 32 u.i., hepatitidis b viri antigenum adnr 10 µg, aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, aluminium 0.2 mg ut aluminii phosphas, natrii chloridum corresp. natrium 1.8 mg, medium 199, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini b sulfas, formaldehydum, polysorbatum 20, polysorbatum 80. ii) hib: polysaccharida haemophili influenzae typus b 20752 conjugata cum toxoido tetani 10 µg, lactosum, aluminium 0.12 mg ut aluminii phosphas, pro praeparatione. i) et ii) corresp. dtpa-hepb-ipv + hib: toxoidum diphtheriae min. 30 u.i., toxoidum tetani min. 40 u.i., toxoidum pertussis 25 µg, haemagglutininum filamentosum (b. pertussis) 25 µg, pertactinum (b. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (stamm mahoney) 40 u.i., virus poliomyelitis typus 2 inactivatus (stamm mef-1) 8 u.i., virus poliomyelitis typus 3 inactivatus (stamm saukett) 32 u.i., hepatitidis b viri antigenum adnr 10 µg, polysaccharida haemophili influenzae typus b 20752 conjugata cum toxoido tetani 10 µg, aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, aluminium 0.32 mg ut aluminii phosphas, natrii chloridum corresp. natrium 1.8 mg, medium 199, lactosum, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini b sulfas, formaldehydum, polysorbatum 20, polysorbatum 80. - vaccinazione primaria e di richiamo, contro difterite, tetano, pertosse, epatite b, poliomielite e haemophilus influenzae di tipo b, a partire dal compimento del 6. settimana di vita - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - toxoidum diphtheriae, toxoidum tetani, bordetellae pertussis antigenum, virus poliomyelitis typus 1 inactivatus, virus poliomyelitis typus 2 inactivatus, virus poliomyelitis typus 3 inactivatus, polysaccharida haemophili influenzae typus b 1482 conjugata cum toxoido tetani - poudre et suspension pour suspension injectable - i) composant dpta-ipv (suspension): toxoidum diphtheriae min. 20 u.i., toxoidum tetani min. 40 u.i., bordetellae pertussis antigenum: toxoidum pertussis 25 µg et haemagglutininum filamentosum 25 µg, virus poliomyelitis typus 1 inactivatus 40 u., virus poliomyelitis typus 2 inactivatus 8 u., virus poliomyelitis typus 3 inactivatus 32 u., aluminium 0.3 mg ut aluminii hydroxidum hydricum ad adsorptionem, formaldehydum, medium 199 cum phenylalaninum 12.5 µg et kalium, acidum aceticum glaciale q.s. ad ph, natrii hydroxidum q.s. ad ph, phenoxyethanolum, ethanolum anhydricum 2 mg, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: neomycinum, streptomycinum, polymyxini b sulfas. ii) composant hib (poudre): polysaccharida haemophili influenzae typus b 1482 conjugata cum toxoido tetani 10 µg, trometamolum, saccharum, acidum hydrochloridum q.s. ad ph, pro praeparatione. - non appena il 2 ° mese fino al 24 ° mese è andato, per l'immunizzazione attiva contro difterite, tetano, pertosse, poliomielite, haemophilus influenzae di tipo b - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - toxoidum diphtheriae, toxoidum tetani, toxoidum pertussis, haemagglutininum filamentosum (b. pertussis), pertactinum (b. pertussis), virus poliomyelitis typus 1 inactivatus (stamm mahoney), virus poliomyelitis typus 2 inactivatus (stamm mef-1), virus poliomyelitis typus 3 inactivatus (stamm saukett) - sospensione iniettabile - toxoidum diphtheriae min. 30 u.i., toxoidum tetani min. 40 u.i., toxoidum pertussis 25 µg, haemagglutininum filamentosum (b. pertussis) 25 µg, pertactinum (b. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (stamm mahoney) 40 u.i., virus poliomyelitis typus 2 inactivatus (stamm mef-1) 8 u.i., virus poliomyelitis typus 3 inactivatus (stamm saukett) 32 u.i., aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum corresp. natrium 1.8 mg, medium 199, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini b sulfas, formaldehydum, polysorbatum 80. - vaccinazione primaria e di richiamo, contro difterite, tetano, pertosse e poliomielite, che abbiano compiuto il 2. mese di vita - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - virus e la poliomielite di tipo 1 inactivatus, virus e poliomielite di tipo 2 inactivatus, virus e poliomielite di tipo 3 inactivatus - soluzione iniettabile - virus poliomyelitis typus 1 inactivatus 40 u., virus poliomyelitis typus 2 inactivatus 8 u., virus poliomyelitis typus 3 inactivatus 32 u., medium 199, polysorbatum 80, conserv.: formaldehydum 0.01 mg, phenoxyethanolum 2.5 mg, residui: neomycini sulfas max.0.05 ng, polymyxini b sulfas max. 0.01 ng, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml. - immunizzazione attiva contro la poliomielite, che abbiano compiuto il 2. mese di vita - vaccini